Aripiprazole Tablet
Product Images NDC 70518-2736

11 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Struct)

Structure (Aripiprazole Struct)
Chemical structure diagram of Aripiprazole, showing its molecular formula with two chlorine atoms attached to a benzene ring linked to a piperazine ring and an indole derivative with a ketone group.*
FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

Aripiprazole_fig_01 (Aripiprazole Fig 01)
A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals in Aripiprazole exposure with various interacting drugs. The y-axis lists drugs including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others like valproate, lithium, and lorazepam. The x-axis shows change relative to a reference with no interacting drug, from 0.5 to 3.0-fold.*
FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

Aripiprazole_fig_02 (Aripiprazole Fig 02)
A figure titled 'Effect of Other Drugs on Aripiprazole' showing dehydro-aripiprazole fold change and 90% confidence intervals for various interacting drugs. The chart plots change relative to a reference (without interacting drug) on the x-axis, with pharmacokinetic parameters AUC and Cmax for different drug categories including CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and others like valproate, lithium, and lorazepam.*
FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

Aripiprazole_fig_03 (Aripiprazole Fig 03)
A scatter plot illustrating the effect of Aripiprazole on various drugs by showing fold change and 90% confidence intervals. The x-axis represents the change relative to a reference without the interacting drug, and the y-axis lists different drugs and pharmacokinetic parameters such as AUC and Cmax. Data points indicate how Aripiprazole affects these parameters for each drug.*
FDA Label Image

Figure4 (Aripiprazole Fig4)

Figure4 (Aripiprazole Fig4)
A chart titled 'Aripiprazole Fold Change and 90% CI' depicting pharmacokinetic data comparing various special populations. The graph shows fold change and confidence intervals for Aripiprazole parameters (AUC, Cmax) across groups including CYP2D6 metabolism status, gender, age, hepatic impairment levels, and severe renal impairment, relative to reference values.*
FDA Label Image

Figure5 (Aripiprazole Fig5)

Figure5 (Aripiprazole Fig5)
A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in pharmacokinetic parameters (AUC and Cmax) relative to a reference. The chart compares the effects of CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment on dehydro-Aripiprazole levels, using horizontal lines with data points representing confidence intervals and relative change values on the x-axis.*
FDA Label Image

Figure6 (Aripiprazole Figure6)

Figure6 (Aripiprazole Figure6)
A Kaplan-Meier curve comparing the proportion with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Number of subjects at risk are indicated below the x-axis for both groups at multiple time points.*
FDA Label Image

Figure7 (Aripiprazole Figure7)

Figure7 (Aripiprazole Figure7)
A Kaplan-Meier survival curve showing the proportion of subjects experiencing relapse over 182 days from randomization. Two groups are compared: Aripiprazole and placebo. The graph plots proportion with relapse on the vertical axis and days from randomization on the horizontal axis, with numbers of subjects at risk indicated below the time points.*
FDA Label Image

Figure8 (Aripiprazole Figure8)

Figure8 (Aripiprazole Figure8)
A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk at several time points below the x-axis.*
FDA Label Image

Figure9 (Aripiprazole Fig9)

Figure9 (Aripiprazole  Fig9)
A line graph depicting the least-squares mean change in YGTSS total tic score from baseline over 8 weeks of treatment. It compares Aripiprazole low dose, Aripiprazole high dose, and placebo groups, showing a decrease in tic scores with increasing treatment time, with the high dose group showing the greatest reduction.*
FDA Label Image

Mm1 (Aripiprazole 2mg 70518 2736 00)

Mm1 (Aripiprazole 2mg 70518 2736 00)
Aripiprazole 2 mg tablet label from RemedyRepack Inc., containing 30 tablets with NDC 70518-2736-00. The label includes storage instructions and repackaging information by RemedyRepack Inc., Indiana, PA. Manufacturer is Ajanta Pharma USA Inc., Bridgewater, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.